This may indicate that the effectiveness of the conjugated CCMs is specific to HER2-overexpressed cells, and the conjugated peptide may be more effective in inhibiting the dimerization of the HER2 receptor, leading to apoptosis of the cancer cells. This evidence concerns the gene ERBB2 and cancer.